INTRODUCTION
Multiple Sulfatase Deficiency (MSD, MIM: #272200) affects the posttranslational activation of newly synthesized sulfatases by the formylglycine-generating enzyme (FGE). 1 FGE is a glycoprotein of the endoplasmatic reticulum, 341 amino acids in length as mature enzyme, but is also secreted after N-terminal proteolytic processing. 2 The crystal structure shows a monomeric fold with two buried calcium ions, cysteine pairs stabilizing the core domain and two catalytic cysteines directly involved in formylglycine-generating redox activity [3] [4] [5] (Supplementary Figure S1) . Mutations in the FGEencoding SUMF1 gene lead to instable protein and/or impaired FGE catalytic function resulting in reduced sulfatase activities. More than 30 different SUMF1 mutations are known, most of them missense mutations that affect stability and residual molecular activity of mutant FGE, which both determine MSD disease severity. 6, 7 The clinical phenotype includes the neonatal very severe, late infantile (severe and mild) and rare juvenile (mild) form. MSD combines main clinical symptoms of different single sulfatase deficiencies like dysmorphic features, neurodegenerative course of disease and ichthyotic skin rash. For patients with a functionally characterized mutation, a prediction of the clinical outcome is possible. [6] [7] [8] [9] Here, we report a patient with two novel SUMF1 mutations, one nonsense and one missense, describe the clinical consequences and correlate this with the molecular defects attributable to the missense mutation.
MATERIALS AND METHODS

SUMF1 mutations and enzyme activity assays
Mutational analysis of the SUMF1 gene from genomic DNA of patient fibroblasts or leukocytes, as well as sulfatase and FGE activity assays were performed as described earlier. 10, 11 Expression studies Cell culturing of patient skin fibroblasts and HT-1080 fibrosarcoma cells as well as stable transfection with pSB-FGE-His plasmids were described earlier. 6, 7 The FGE-E130D mutation was created by site-directed mutagenesis according to the QuikChange Protocol (Stratagene, La Jolla, CA, USA) with Pfu polymerase and complementary primer pairs (coding sequence only: FGE_ E130D-His_c 5 0 -CATGGATGCCTATGATGTCAGTAATACTG-3 0 ).
Western blot and immunofluorescence studies
Aliquots of 50-mg cell protein, from cells of a confluent T75 cell culture flask grown in 10 ml medium for 24 h, and 40 ml aliquots of this medium were analyzed by SDS-polyacrylamide gel electrophoresis and western blot using a polyclonal FGE antibody or monoclonal His antibody (Sigma Aldrich, Munich, Germany) as described. 2 Endogenous FGE in skin fibroblasts or variant FGE in stably transfected HT-1080 cells was detected by indirect immunofluorescence using a polyclonal rabbit FGE antibody as described. 2 Monoclonal antibodies as organelle markers were used against PDI (Biomol, Hamburg, Germany), LAMP1 (Abcam, Cambridge, UK) and Golgi protein 58K (Abcam, Cambridge, UK). Confocal images were taken on a Leica TCS SP2 AOBS laser-scanning microscope and analyzed with the manufacturer's software (Leica, Solms, Germany).
FGE purification
HT-1080 cells stably overexpressing His-tagged wildtype or FGE-E130D were harvested, resuspended in buffer I (20 mM Tris-HCl, 40 mM imidazole, 500 mM sodium chloride, pH 8.0), and sonicated in presence of a protease inhibitor cocktail (Sigma Aldrich, Munich, Germany). The cell lysate was cleared by centrifugation at 100 000 Â g for 20 min and loaded on a HisTrap column (GE Healthcare, Munich, Germany) using buffer I. The column was eluted in fractions of 1 ml with buffer II (20 mM Tris-HCl, 500 mM sodium chloride 500 mM imidazole, pH 8.0) running a gradient from 0-100% of buffer II in 25 min on a Ä KTA system (GE Healthcare). Appropriate elution fractions were pooled (6-8 ml), and concentrated to 50 ml using Amicon centrifugation filter units (Millipore, Billerica, MA, USA). The concentrated eluate was dialyzed against buffer III (20 mM Tris-HCl, pH 8), its FGE amount was determined and used for FGE activity assays.
Metabolic labeling and immunoprecipitation
HT-1080 cells stably expressing FGE-His or FGE-E130D-His were subjected to metabolic labeling with 35 S-methionine/cysteine and immunoprecipitation followed by phosphorimaging and densitometric quantification (PMI System, Biorad, Munich, Germany) as described. 7 
RESULTS
A patient with MSD displays a late infantile severe phenotype and reduced sulfatase activities The female patient was born as the second child of non-consanguineous parents from Switzerland. In the first months she presented with muscular hypotonia and had a consecutive developmental delay. She was able to sit at age 14 months; at age 20 months she could grasp, babble, and was visually interactive. At age 22 months progressive leg spasticity became obvious, followed by paroxysmal tonic upward eye movements at age 25 months. At this time she started to lose motor and visual skills. Cerebral magnetic resonance imaging at age 27 months displayed a leukoencephalopathy pattern as seen in metachromatic leukodystrophy. Laboratory examinations revealed high-urine concentrations of glycosaminoglycans as well as clearly reduced activity of three cellular sulfatases tested (Table 1) . At age 31 months she showed signs of tetraplegia, long eye lashes, a dry and scaly skin and no more reactions to noises. At 4 years Table 1 Residual activities of selected sulfatases in patient fibroblasts ASA activity a ASC activity a Gal-6-S activity a nmol/h per mg
a Activities þ / À SD were assayed in total cell lysates and calculated from three independent experiments. b An unaffected fibroblast cell line served as control. c % activity in patient compared to control is highlighted in bold. The clinical characteristics of the patient are highlighted in bold.
and 1 month, coarse facies and dysostosis multiplex were detected, organomegaly was still absent. From the age of 39 months on she had irregular breathing attacks due to intermittent central hypoventilation. She died at the age of 5 years and 5 months (for a clinical synopsis see Table 2 ). The course of the disease in this patient could be classified as late infantile severe form of MSD. The early onset of neurodegeneration in the second year of life and the disease progression due to the manifestation of several additional clinical symptoms throughout her life is comparable to other described late infantile severe cases of MSD. [6] [7] [8] Two new MSD causing SUMF1 mutations In this patient we identified two so far unknown SUMF1 mutations. c.156delC leads to a frameshift and premature stop codon (p.C52fsX57). On the other allele, the single nucleotide exchange c.390A4T substitutes glutamate at position 130 of FGE by aspartate. At the mRNA level only the nucleotide exchange c.390A4T was detectable (data not shown).
FGE-E130D
: correct intracellular localization, exceptionally high residual activity but drastically impaired intracellular stability and no secretion Endogenous FGE-E130D in patient fibroblasts was hardly detectable (Supplementary Figure S2) . For detailed analysis we expressed recombinant His-tagged FGE-E130D in human HT-1080 fibrosarcoma cells. FGE-E130D was correctly localized in the endoplasmatic reticulum (Figure 1a) . Western blot analysis (Figure 1b) revealed that FGE-E130D was not secreted, whereas a major fraction of wildtype FGE was secreted in a N-terminally truncated form (38 kDa, starting at glutamate-73) due to proteolytic processing during secretion, as described previously. 2 Pulse-chase analysis by metabolic 35 S-labeling indicated a severe reduction of the intracellular stability of FGE-E130D, such that about 90% of the protein was degraded within 3 h (Figure 1d ). Partially purified FGE-E130D displayed a residual FGE activity of 55 þ / À16% (Figure 1c ). Of note, the intracellular FGE-E130D was present in two molecular forms, one with a molecular mass of 41 kDa, comparable to wildtype FGE, and the other with 43-44 kDa. Endoglycosidase H treatment converted both forms to a 39-kDa form (data not shown).
DISCUSSION
MSD is still an untreatable disease. Thus, potential treatment approaches, and also genetic counseling, directly depend on thorough analyses of the functional consequences of human SUMF1 mutations on the clinical and biochemical phenotype. In a severely affected MSD patient with the late infantile onset of disease we identified and characterized two yet undescribed SUMF1 mutations, namely c.156delC and c.390A4T. As no corresponding mRNA for the single nucleotide deletion (p.C52fsX57) could be detected, probably in consequence of nonsense mediated decay, 12 the resulting sulfatase acitivities and apparently also the clinical phenotype are due to the missense mutation c.390A4T leading to expression of FGE-E130D protein.
The E130D mutation severely destabilizes FGE Missense mutations represent the majority of genetic defects in MSD. For eight different missense mutations the instability of mutant FGE, as predicted from the crystal structure, could be verified by stability and residual activity measurements. 4, 6, 7 In FGE-E130D the aspartate-130 side-chain is too short to position one of two calcium ions in the coordination plane. Consequently, interactions with adjacent residues are disturbed (Supplementary Figure S1) leading to protein destabilization and most likely early degradation. 13 Indeed, we could show that FGE-E130D is unable to pass endoplasmatic reticulum quality control, hence getting rapidly and completely degraded inside cells without entering into secretion. Interestingly, we found expression of FGE-E130D with two different molecular weights in all experiments and even after purification (Figures 1b-d) . Both forms were sensitive to treatment with endoglycosidase H leading to a deglycosylated 39-kDa protein (data not shown). Details of these two alternative glycosylation patterns remain to be elucidated.
FGE-E130D displays very high residual catalytic activity
Up to now, all structurally impaired FGE variants showed clearly reduced specific enzyme activity. 6, 7 The residual catalytic activities have been determined with purified FGE variants and reflect the true molecular enzymatic capacity of the mutant proteins in vitro. FGE-E130D shows a remarkable residual activity (55% compared with wildtype). So far, this is the highest residual activity that has been reported for a mutant FGE found in MSD. Such a high activity, if true in vivo, would be more than enough to maintain full sulfatase activation. However, the patient's compromised activities of sulfatases are in the range of no more than 10-20% of control activities, hence indicating massive FGE deficiency. This obviously is a consequence of the rapid degradation of FGE-E130D. Thus, protein instability is the leading molecular factor for pathophysiology in the reported patient.
Genotype-phenotype relationship in severe late infantile MSD
The clinical course of MSD in the reported patient corresponds to the late infantile severe form. Generally, MSD patients with high residual FGE activity, but instable protein reveal an attenuated course of disease. 6, 7 In contrast to FGE-E130D, as reported here, all other mutant FGE proteins with high residual activity in former studies were found to be secreted. This indicates that these mutants at least in part were successful to pass intracellular control mechanisms of protein folding. The specific biochemical feature of a rapidly degraded (and hence non-secreted) FGE-E130D almost certainly contributes to the late infantile severe phenotype of our patient, thereby highlighting the importance of affected FGE stability and protein degradation as a main pathophysiological cause for MSD and as a reliable indicator of disease severity in case of high residual FGE activity. This does not exclude that other so far undiscovered disease modifiers also influence the clinical phenotypes of MSD patients. Our patient report underlines that potential future therapies should aim at protein stabilization mechanisms Àin particular when residual mutant FGE activities are high.
